A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy

In a study published in Cancer Discovery, cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells.